@article{garin2015sitagliptinassociated,
  title = {Sitagliptin-Associated Pancreatitis: A Report of 4 Cases},
  author = {Aude Garin and Florence Bouilloud and Emmanuelle Masson and Olivier Blétry and Alfred Penfornis and Pascal Hammel},
  year = 2015,
  url = {https://ibimapublishing.com/articles/IJCRM/2015/199809/},
  journal = {International Journal of Case Reports in Medicine},
  volume = 2015 (2015),
  pages = 7,
  doi = 10.5171/2015.199809,
  abstract = {Objective: Sitagliptin is a new oral glucose-lowering medication that acts via the incretin hormone system. The most common side-effects are headache and pharyngitis. Acute pancreatitis is rarely described in literature. Research design and Methods: We report four cases of pancreatitis that developed in patients after 9 days to 18 months of treatment with sitagliptin. Result: The origin of acute pancreatitis has been attributed to the administration of sitagliptin after a thorough analysis of the different possible etiologies with different accountabilities defined by Delcenserie R. (2001) as the time of onset criteria, the existence or not of other metabolic, toxic or genetic causes.Conclusion: Acute pancreatitis in patients receiving sitagliptin seems to be rare but physicians should be aware of this possibility.},
  keywords = {Sitagliptin, DPP-4 inhibitor, acute pancreatitis},
  note = Article ID: 199809
}